Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT04572906

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

Conditions: Peripheral Nerve Injuries

Sex: All
Ages: 12 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 51
Sponsor: Neuraptive Therapeutics Inc.

Location: UF Health - University of FL - Gainesville Gainesville Florida

Summary

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 16 and 80 years of age.

Eligibility Criteria

Inclusion Criteria: * The subject is at least 12 years of age and not older than 80. * The subject has sustained a confirmed (intra-op assessment) single transected peripheral nerve injury. * The subject's nerve injury is classified as Sunderland's Fourth and Fifth Degree (Class III) * The subject's nerve injury is amenable to minimal or acceptable tension, in direct, end-to-end repair. * The surgical repair will occur within 48 hours of injury. Exclusion Criteria: * The subject has a PNI with a segmental loss (gap) that cannot be repaired with minimal or acceptable tension. * Other treatments known to affect the growth and/or physiology of the neural and vascular system. * The nerve injury has vascular damage that cannot be repaired to provide adequate perfusion of the injured site. * The subject is pregnant and/or is breastfeeding. * The subject has a significant medical comorbidity precluding immediate repair.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04572906). StuddyBuddy aggregates publicly available trial information.